A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants with Advanced Unresectable or Metastatic Solid Tumors
Public ClinicalTrials.gov record NCT05572684. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1b/2, Open-Label, Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab for Participants with Advanced Unresectable And/or Metastatic Immune Checkpoint Inhibitor (ICI) Refractory Solid Tumors or ICI Naïve MSS/MSI-Low Solid Tumors
Study identification
- NCT ID
- NCT05572684
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- NextCure, Inc.
- Industry
- Enrollment
- 97 participants
Conditions and interventions
Conditions
Interventions
- NC410 Drug
- pembrolizumab Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 5, 2022
- Primary completion
- Jun 30, 2025
- Completion
- Oct 31, 2025
- Last update posted
- Dec 15, 2024
2022 – 2025
United States locations
- U.S. sites
- 17
- U.S. states
- 11
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Arizona Oncology Associates | Tucson | Arizona | 85711 | — |
| Rocky Mountain Cancer Centers | Aurora | Colorado | 80012 | — |
| St. Elizabeth Edgewood Hospital | Edgewood | Kentucky | 41017 | — |
| Ochsner Cancer Institute | New Orleans | Louisiana | 70121 | — |
| Johns Hopkins Sidney Kimmel Comprehensive Cancer Center | Baltimore | Maryland | 21231 | — |
| Hackensack Meridian Health University Medical Center- John Theurer Cancer Center | Hackensack | New Jersey | 07601 | — |
| Roswell Park Comprehensive Cancer Center | Buffalo | New York | 14203 | — |
| NYU Langone Health | New York | New York | 10016 | — |
| University of Cincinnati Cancer Center | Cincinnati | Ohio | 45267 | — |
| UT Southwestern Medical Center | Dallas | Texas | 75235 | — |
| Texas Oncology - Baylor Charles A. Sammons Cancer Center | Dallas | Texas | 75246 | — |
| MD Anderson Cancer Center | Houston | Texas | 77030 | — |
| UT Health San Antonio | San Antonio | Texas | 78229 | — |
| Texas Oncology - San Antonio | San Antonio | Texas | 78240 | — |
| Inova Schar Cancer Institute | Fairfax | Virginia | 22031 | — |
| Virginia Cancer Specialist | Fairfax | Virginia | 22031 | — |
| Northwest Cancer Specialist | Vancouver | Washington | 98684 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05572684, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 15, 2024 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05572684 live on ClinicalTrials.gov.